- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06690775
CATALINA-2: um estudo de fase 2 de TORL-1-23 em câncer de ovário avançado.
Catalina-2: um estudo de fase 2 avaliando a eficácia e segurança de TORL-1-23 em mulheres com câncer epitelial de ovário avançado resistente à platina (incluindo câncer peritoneal primário e das trompas de falópio) expressando Claudina 6
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Baden-Wurttenberg
-
Heidelberg, Baden-Wurttenberg, Alemanha, 69120
- Universitatsklinikum Heidelberg
-
-
Bavaria
-
Erlangen, Bavaria, Alemanha, 91054
- Universitätsklinikum Erlangen
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Alemanha, 20246
- Universitätsklinikum Hamburg-Eppendorf, Clinic for Gynecology
-
-
State of Berlin
-
Berlin, State of Berlin, Alemanha, 13353
- Charité Universitätsmedizin Berlin
-
-
-
-
Melbourne
-
Clayton, Melbourne, Austrália, VIC 3168
- Monash Medical Centre
-
-
New South Wales
-
Blacktown, New South Wales, Austrália, 2148
- Blacktown Hospital
-
-
Queensland
-
Chermside, Queensland, Austrália, QLD 4032
- Icon Cancer Centre Chermside
-
-
South Australia
-
Bedford Park, South Australia, Austrália, 5042
- Flinders Medical Centre
-
-
Western Australia
-
Perth, Western Australia, Austrália, WA 6009
- Linear Clinical Research
-
-
-
-
Antwerp
-
Edegem, Antwerp, Bélgica, 2650
- Antwerp University Hospital (UZA)
-
-
Brussels Capital
-
Woluwe-Saint-Lambert, Brussels Capital, Bélgica, 1200
- Cliniques Universitaires Saint-Luc
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Bélgica, 3000
- UZ Leuven
-
-
Wallonia
-
Liège, Wallonia, Bélgica, B-4000
- CHU Liège
-
-
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, Canadá, V2S 0C2
- BC Cancer - Abbotsford
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- British Columbia Cancer Agency (BC Cancer, part of the Provincial Health Services Authority)
-
-
Ontario
-
Toronto, Ontario, Canadá, M4N 3M5
- Sunnybrook Research Institute
-
Toronto, Ontario, Canadá, M5G 2M9
- Princess Margaret Cancer Centre - University Health Network (UHN)
-
-
Quebec
-
Montreal, Quebec, Canadá, H3T 1E2
- Sir Mortimer B. Davis Jewish General Hospital
-
Montreal, Quebec, Canadá, H1T 2M4
- Hospital Maisonneuve Rosemont
-
Montreal, Quebec, Canadá, H2X 0C2
- Centre Hospitalier de l'Universite de Montreal (CHUM)
-
Montreal, Quebec, Canadá, H4A 3J1
- McGill University Health Centre (MUHC) - Royal Victoria Hospital
-
-
-
-
Singapore
-
Singapore, Singapore, Cingapura, 119074
- National University Cancer Institute
-
Singapore, Singapore, Cingapura, 168583
- National Cancer Centre
-
Singapore, Singapore, Cingapura, 217562
- Curie Oncology (Farrer)
-
-
-
-
Gangnam-Gu
-
Seoul, Gangnam-Gu, Coréia do Sul, 06351
- Samsung Medical Center
-
-
Gwanak-gu
-
Seoul, Gwanak-gu, Coréia do Sul, 03080
- Seoul National University Hospital
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Coréia do Sul, 10408
- National Cancer Center
-
Seongnam-si, Gyeonggi-do, Coréia do Sul, 14396
- CHA University Bundang Medical Center
-
-
Seocho-Gu
-
Seoul, Seocho-Gu, Coréia do Sul, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
-
Seodaemun-Gu
-
Seoul, Seodaemun-Gu, Coréia do Sul, 03722
- Yonsei University Health System, Severance Hospital
-
-
Songpa-Gu
-
Seoul, Songpa-Gu, Coréia do Sul, 05505
- Asan Medical Center
-
-
-
-
Catalonia
-
Girona, Catalonia, Espanha, 17007
- Institut Catalá d'Oncologia de Girona
-
-
Madrid
-
Madrid, Madrid, Espanha, 28034
- Hospital Universitario Ramón y Cajal
-
Madrid, Madrid, Espanha, 28006
- Hospital Clinico San Carlos
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Mayo Clinic Hospital
-
Tucson, Arizona, Estados Unidos, 85711
- TMC HealthCare
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City of Hope National Medical Center
-
Fullerton, California, Estados Unidos, 92835
- Providence St. Jude Medical Center
-
Los Angeles, California, Estados Unidos, 90095
- UCLA - JCCC Clinical Research Unit
-
Palo Alto, California, Estados Unidos, 94304
- Stanford Cancer Center
-
Santa Barbara, California, Estados Unidos, 93105
- SCRI - Sansum Clinic
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Hospital - Anschutz Cancer Pavilion
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Smilow Cancer Hospital at Yale - New Haven
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Mayo Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Winship Cancer Institute, Emory University
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Medical Center
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos, 21401
- SCRI - Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55404
- University of Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55404
- SCRI - Minnesota Oncology Hematology, P.A.
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63108
- Washington University
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Rutgers Cancer Institute
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Duke Cancer Center
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- The James Cancer Hospital and Solove Research Institute - Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Stephenson Cancer Center at the University of Oklahoma
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97227
- SCRI - Northwest Cancer Specialists, P.C.
-
-
Pennsylvania
-
Doylestown, Pennsylvania, Estados Unidos, 18901
- SCRI - Alliance Cancer Specialists, PC
-
Philadelphia, Pennsylvania, Estados Unidos, 19104-4238
- University of Pennsylvania
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- The West Clinic, PLLC dba West Cancer Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- University of Texas Southwestern Medical Center
-
Fort Worth, Texas, Estados Unidos, 76104
- SCRI - Texas Oncology
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 23502
- SCRI - Virginia Oncology Associates
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- Providence Swedish Cancer Institute
-
-
-
-
Auvergne- Rhôn-Alpes
-
Lyon, Auvergne- Rhôn-Alpes, França, 69008
- Centre Leon Berard
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, França, 44805
- Institut de Cancérologie de l'Ouest
-
-
Île-de-France Region
-
Villejuif, Île-de-France Region, França, 94805
- Institut Gustave Roussy
-
-
-
-
Connacht
-
Galway, Connacht, Irlanda, H91YR71
- University Hospital Galway
-
-
Leinster
-
Dublin, Leinster, Irlanda, D07 R2WY
- Start Dublin - Mater Misericordiae University Hospital
-
Dublin, Leinster, Irlanda, DO8C9X2
- St. James Hospital
-
-
-
-
Apulia
-
Bari, Apulia, Itália, 70124
- IRCCS Giovani Paolo II - Instituto Oncologico
-
-
Milano
-
Milan, Milano, Itália, 20159
- Humanitas San Pio X
-
-
Prato
-
Prato, Prato, Itália, 59100
- Nuovo Ospedale di Prato S Stefano
-
-
Rome
-
Rome, Rome, Itália, 00168
- Fondazione Policlinico Universitario A. Gemelli IRCCS
-
-
-
-
Moravian-Silesian
-
Nový Jičín, Moravian-Silesian, Tcheca, 74101
- Hospital Agel, Nový Jičín
-
Ostrava, Moravian-Silesian, Tcheca, 708 52
- University Hospital Ostrava
-
-
Prague
-
Libeň, Prague, Tcheca, 180 81
- Fakultni Nemocnice Bulovka Gynekologicko-Porodinická Klinika
-
Prague, Prague, Tcheca, 120 00
- Vesobecna Fakultni Nemocnice Klinika Gynekologie, Porodnictvi a Neonatologie
-
-
-
-
Styria
-
Graz, Styria, Áustria, 8036
- Medizinische Universitat Landeskrankenhaus Graz
-
-
Tyrol
-
Innsbruck, Tyrol, Áustria, 6020
- Universitatsklinik Innsbruck
-
-
Upper Austria
-
Linz, Upper Austria, Áustria, 4010
- Ordensklinikum Linz
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Participants are eligible to be included in the study only if all the following criteria apply:
-
Females ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the informed consent.
-
Participants must sign the informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
-
Disease Type:
- Histologically or cytologically confirmed diagnosis of advanced (unresectable) or metastatic high grade serous ovarian, primary peritoneal (i.e, of primary origin), or fallopian tube cancer. High-grade endometrioid ovarian cancer is permitted for enrollment.
- Participant's tumor must be positive for CLDN6 expression as defined by the CLDN6 reference laboratory assay. Tumor tissue will be required for submission for CLDN6 testing prior to Cycle 1 Day 1.
- Participants must have platinum-resistant disease, defined as the following:
- If participants received only 1 line of platinum-based therapy, they must have completed 4 or more cycles of platinum-containing therapy, must have achieved a CR or PR, and progressed >3 months but ≤6 months after the last dose of platinum.
- Participants who have received more than 1 line of platinum- based therapy must have progressed on or within 6 months after the last dose of platinum.
- NOTE: This should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression (per RECIST v1.1).
- Participants who are platinum-refractory during front-line treatment are excluded.
- Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single- agent therapy is appropriate as the next line of treatment. Study rules for evaluation of number of prior systemic lines of therapy:
- Adjuvant ± neoadjuvant is considered one line of therapy
- Maintenance therapy (eg, bevacizumab or PARP inhibitors) will be considered part of the preceding line of therapy (ie, not counted independently)
- Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)
- Hormonal therapy will not be counted as a separate line of therapy
-
Measurable disease, per RECIST v1.1
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
-
Adequate organ function, based on the following laboratory values:
-
ANC: ≥1,500/mcL
-
Platelets: ≥100,000/mcL without transfusion within 4 weeks of first dose
-
Hemoglobin: 9 g/dL with transfusion or EPO support up to 14 days before eligibility assessment
-
Measured or calculated creatinine clearance with a validated formula*: ≥30 mL/min
-
Serum total bilirubin: ≤1.5 X ULN (participants with known Gilbert disease or liver metastases who have serum bilirubin level ≤3×ULN may be enrolled
-
AST (SGOT) and ALT (SGPT): ≤3 X ULN (participants with active liver metastases who have ALT/AST ≤5 X ULN may be enrolled)
-
Albumin: ≥2.5 g/dL
-
ECG: 12-Lead ECG with normal tracing or non-clinically significant changes that do not require medical intervention and QTcF interval
- 470 msec and without history of Torsades des Pointes or other symptomatic QTc abnormality.
-
-
Participants of childbearing potential must have a negative serum pregnancy test within 72 hours before starting study drug treatment. The serum pregnancy test must be negative for the participant to be eligible.
-
Participants must agree to use a highly effective birth control method from the time of the first study drug treatment through 7 months after the last study drug treatment, or be of nonchildbearing potential.
-
Participants must agree not to donate eggs from the first study drug treatment through 7 months after the last study drug treatment.
-
Participants must agree to not breastfeed from the first dose of study treatment through 90 days after the last dose of study treatment.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
-
Has not recovered [recovery is defined as National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade ≤1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
-
Participants with clear cell, mucinous, sarcomatous (including carcinosarcoma), mixed histology, or low-grade, borderline ovarian tumors or non-epithelial ovarian cancers.
-
Participants with primary platinum-refractory ovarian, primary peritoneal (i.e. of primary origin) or fallopian tube cancer, defined as disease that did not respond to or has progressed within 3 months of the last dose of first line platinum-containing chemotherapy.
-
Received prior chemotherapeutic, investigational, radiotherapy, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23. There is no waiting period required for stereotactic radiosurgery.
-
Prior treatment with a CLDN6-targeting agent or an MMAE-containing ADC.
-
Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded.
-
Grade 2 or greater peripheral neuropathy.
-
History of non-infectious pneumonitis/ILD within 6 months of first dose of study drug.
-
Participants must not be considered a high medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
-
History of significant cardiac disease:
- Congestive heart failure >New York Heart Association class 2 within last year
- Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
- Myocardial infarction less than 6 months before start of study drug
- Anti-arrhythmic therapy (beta blockers are permitted)
- Any unstable ischemic disease or untreated arrhythmia
-
Known history of myelodysplastic syndrome or acute myeloid leukemia.
-
History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. Participants with malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ of the breast are not excluded.
-
Uncontrolled infection; active, clinically serious infections (CTCAE Grade >2).
-
Participants with seizure disorder requiring medication.
-
Known hypersensitivity or intolerance to any of the study drugs, study drug classes, or excipients in the formulation.
-
History of having an allogeneic bone marrow or organ transplant.
-
Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator.
-
Participants who are taking any drugs that are strong inducers and/or strong inhibitors of CYP3A4 enzymes.
-
Participants who are taking any drugs that are inhibitors of P-glycoprotein.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort 1
Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle. |
2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle. 3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle. 3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle. 6.0 mg subcutaneous injection on Day 4 of each cycle. |
|
Experimental: Cohort 2
Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle. |
2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle. 3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle. 3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle. 6.0 mg subcutaneous injection on Day 4 of each cycle. |
|
Experimental: Cohort 3
Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle. |
2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle. 3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle. 3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle. 6.0 mg subcutaneous injection on Day 4 of each cycle. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced PROC expressing CLDN6
Prazo: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
Objective Response Rate (ORR) per RECIST v1.1 by Blinded Independent Central Review (BICR) |
At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Duration of Response (DOR)
Prazo: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by Blinded Independent Central Review (BICR) and investigator assessment |
At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
|
Objective Response Rate (ORR)
Prazo: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by investigator assessment |
At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
|
Progression-free Survival (PFS)
Prazo: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by Blinded Independent Central Review (BICR) and by investigator assessment |
At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
|
Overall Survival (OS)
Prazo: From time of consent until death or completion of study (Study duration is approximately 40 months)
|
To assess additional efficacy outcome measures of TORL-1-23 |
From time of consent until death or completion of study (Study duration is approximately 40 months)
|
|
Incidence and severity of AEs and clinical laboratory abnormalities per CTCAE v5.0
Prazo: From informed consent until 30 days after the last dose of study treatment, approximately 24 months (each cycle is 21 days)
|
To assess the safety and tolerability of TORL-1-23 |
From informed consent until 30 days after the last dose of study treatment, approximately 24 months (each cycle is 21 days)
|
|
CA-125 response per Gynecological Cancer Intergroup (GCIG) criteria
Prazo: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
To assess the pharmacodynamic effects of TORL-1-23 |
At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Doenças do Sistema Endócrino
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Neoplasias por Tipo Histológico
- Doenças Genitais Femininas
- Neoplasias das Glândulas Endócrinas
- Neoplasias Glandulares e Epiteliais
- Doenças ovarianas
- Doenças anexiais
- Neoplasias Genitais Femininas
- Distúrbios Gonadais
- Carcinoma
- Doenças das Trompas de Falópio
- Neoplasias ovarianas
- Carcinoma Epitelial Ovariano
- Neoplasias das Trompas de Falópio
- pegfilgrastim
- Preparações farmacêuticas
Outros números de identificação do estudo
- TORL123-002
- 2024-517190-24-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .